Stratification of patients with bladder cancer for cystoscopic surveillance
Lead Participant:
CYTOSYSTEMS LIMITED
Abstract
Cytosystems Ltd has been researching the potential to assess bladder cancer by means of a urine test.
Its research over a 6 year period has led to a greater understanding of the challenges of collecting and
processing urine samples and detecting the presence of cancerous cells. This project will allow the urine
collection and processing to be easily carried out in the clinic or general practice followed by an
automated system to analyse the cancerous cells, potentially avoiding the need for bladder cancer
patients to undergo uncomfortable cystocopy during routine surveillance after treatment.
Bladder cancer is the 4th most common cancer in men and 7th in women and is one of the most
expensive to manage, this new test should significantly reduce costs and deliver more patient comnfort
without compromising patient safety.
Its research over a 6 year period has led to a greater understanding of the challenges of collecting and
processing urine samples and detecting the presence of cancerous cells. This project will allow the urine
collection and processing to be easily carried out in the clinic or general practice followed by an
automated system to analyse the cancerous cells, potentially avoiding the need for bladder cancer
patients to undergo uncomfortable cystocopy during routine surveillance after treatment.
Bladder cancer is the 4th most common cancer in men and 7th in women and is one of the most
expensive to manage, this new test should significantly reduce costs and deliver more patient comnfort
without compromising patient safety.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
  | ||
Participant |
||
CYTOSYSTEMS LIMITED |
People |
ORCID iD |
Helen Mill (Project Manager) |